These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21668683)

  • 1. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years.
    Ambrose CS; Yi T; Falloon J
    Influenza Other Respir Viruses; 2011 Nov; 5(6):389-97. PubMed ID: 21668683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing.
    Ambrose CS; Dubovsky F; Yi T; Belshe RB; Ashkenazi S
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2549-57. PubMed ID: 22410646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age.
    Toback SL; Ambrose CS; Eaton A; Hansen J; Aukes L; Lewis N; Wu X; Baxter R
    Vaccine; 2013 Apr; 31(14):1812-8. PubMed ID: 23395734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.
    Ortiz JR; Goswami D; Lewis KD; Sharmeen AT; Ahmed M; Rahman M; Rahman MZ; Feser J; Neuzil KM; Brooks WA
    Vaccine; 2015 Jun; 33(29):3415-21. PubMed ID: 25917680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.
    Baxter R; Toback SL; Sifakis F; Hansen J; Bartlett J; Aukes L; Lewis N; Wu X; Ambrose CS
    Vaccine; 2012 Apr; 30(19):2989-98. PubMed ID: 22386746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.
    Tennis P; Toback SL; Andrews EB; McQuay LJ; Ambrose CS
    Vaccine; 2012 Sep; 30(42):6099-102. PubMed ID: 22841479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
    King JC; Fast PE; Zangwill KM; Weinberg GA; Wolff M; Yan L; Newman F; Belshe RB; Kovacs A; Deville JG; Jelonek M;
    Pediatr Infect Dis J; 2001 Dec; 20(12):1124-31. PubMed ID: 11740317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age.
    Baxter R; Toback SL; Sifakis F; Hansen J; Bartlett J; Aukes L; Lewis N; Wu X; Ambrose CS
    Vaccine; 2012 Apr; 30(20):3053-60. PubMed ID: 22425787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
    Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
    Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years.
    Baxter R; Eaton A; Hansen J; Aukes L; Caspard H; Ambrose CS
    Vaccine; 2017 Mar; 35(9):1254-1258. PubMed ID: 28162825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years.
    Block SL; Toback SL; Yi T; Ambrose CS
    Clin Ther; 2009 Oct; 31(10):2140-7. PubMed ID: 19922885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*.
    Sheldon EA; Jeanfreau R; Sliman JA; Charenkavanich S; Rousculp MD; Dubovsky F; Mallory RM
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1142-50. PubMed ID: 23061976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.
    Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A
    Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
    J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.
    Carter NJ; Curran MP
    Drugs; 2011 Aug; 71(12):1591-622. PubMed ID: 21861544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies.
    Ambrose CS; Wu X; Knuf M; Wutzler P
    Vaccine; 2012 Jan; 30(5):886-92. PubMed ID: 22155144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.
    Belshe RB; Ambrose CS; Yi T
    Vaccine; 2008 Sep; 26 Suppl 4():D10-6. PubMed ID: 18611422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live attenuated influenza vaccine in children.
    Ambrose CS; Walker RE; Connor EM
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):206-12. PubMed ID: 17055372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.